IBCSG Tissue Bank Policy
|
|
- Russell Shaw
- 2 years ago
- Views:
Transcription
1 THE INTERNATIONAL BREAST CANCER STUDY GROUP IBCSG Tissue Bank Policy Accepted by the IBCSG Executive Committee on March 24, 2006 Accepted by the IBCSG Ethics Committee on March 24, 2006 Accepted by the IBCSG Foundation Council on August 7, 2006 v.2 June 2010 IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 1/7
2 1. Introduction The IBCSG maintains a Tissue Bank of formalin-fixed, paraffin-embedded tissue specimens. It contains specimens from the majority of patients included in clinical trials conducted by the group since This high-quality material is being used for correlative studies that relate markers to clinical outcomes documented during the conduct and follow-up of our clinical trials. The purpose of such research is to improve our knowledge on the prevention, diagnosis and treatment of breast cancer. This document outlines the current IBCSG policy and describes the organization of the IBCSG Tissue Bank. 2. Policy IBCSG collects formalin-fixed, paraffin-embedded tissue from most patients included in IBCSG trials. The specimens are used for Central Pathology Review by the reference pathologist appointed for the trial, and for any translational research specified in the trial protocol. Central pathology review, which includes immunohistochemistry characterization is integral to the IBCSG Trials. From the formalin fixed paraffin embedded blocks transferred to the IBCSG. cores will be punched to construct Tissue Micro Arrays (TMA). All FFPE blocks, TMA blocks, or other derivatives thereof, will be logged in the IBCSG Pathology Material Tracking System and banked in the IBCSG Tissue Bank to have available for translational research. This high-quality material is kept for future research/ translational research that is not yet specified at the time of collection. Collection, shipping, storage and research are done under strict observation of patients rights and confidentiality. The IBCSG Tissue Bank and the IBCSG Central Pathology Office are located at the European Institute of Oncology in Milan, Italy.. The material collected is, in principle, regarded as donated by the patients for research. There is no international consensus on the issue of ownership of material. IBCSG therefore has custodianship of the samples. The material is used in research projects proposed by IBCSG investigators or scientists outside of IBCSG. Collaboration with commercial companies is not excluded, but no material will be sold for profit. All institutions who receive specimen samples for research projects must adhere to the same ethical standards as IBCSG. In rare cases, intellectual property may arise from a research project. The intellectual property rights will remain with IBCSG and any financial gain will be reinvested in IBCSG research. All material is kept for an indefinite length of time. No FFPE blocks are destroyed. Material is sent back to the pathologist if requested. IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 2/7
3 Should IBCSG decide to stop pursuing the IBCSG Tissue Bank, it would pass the Tissue Bank on to a non-profit research organization adhering to the same ethical standards, but would not sell it. 3. Governance The IBCSG Tissue Bank is under the ultimate responsibility of the IBCSG Foundation Council. The IBCSG Biological Projects Working Group (BPWG) serves as an advisory committee to the Executive Committee on the scientific value and the priority of research projects and the proper use of the material. The IBCSG Executive Committee decides on all submitted projects and involves the Foundation Council where appropriate. Any research project using material from the IBCSG Tissue Bank must be approved by the IBCSG Ethics Committee. The IBCSG Director supervises the Central Pathology Office. The Principal Investigator of any research facility to which tissue material, or any derivatives thereof, is shipped for a specific project signs a written agreement with IBCSG stating the use of the material and the rules applicable for surplus material. Material which can be used for further projects must be shipped back to the IBCSG Tissue Bank. All publications arising from such projects will follow the IBCSG Guidelines for Presentation and Publication (Appendix 3) 4. Ethical considerations IBCSG is the custodian of all patients tissue material. As such, IBCSG will make optimal use of the material for research purposes, while guarding the patients interests. The protection of the patients rights and safety are the basis for the maintenance and use of the IBCSG Tissue Bank. The collected tissue specimens are used according to the written consent obtained from the patient. The Patient Information Sheet and Informed Consent (PIS/IC) are developed according to IBCSG standards and must be adapted to local laws and regulations (see Appendix 1, PIS/IC template). The confidentiality of the patients is maintained by coding all material specimens with a unique patient identifier at the participating center, even before the material is provided to the IBCSG Tissue Bank... The patient identifier corresponds to the one used in the clinical database of the trial. All samples and derivatives thereof are being provided to researchers as anonymized, with a IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 3/7
4 Translational Research Identifier (TRI), a laboratory reference number. This TRI effectively inhibits the identification of patients and only permits the correlation with clinical data in the IBCSG database. All samples shipped from the IBCSG Central Pathology Office to a research facility is marked exclusively with this identifier and cannot be linked to the patient s name or origin by the recipient. Access to patient identification is restricted to personnel at the treating institution. Personnel of the IBCSG Coordinating Center, the Central Pathology Office, the Data Management Center and Statistical Center can link the specimen to the patient s data in the clinical database, but not to the patient s name (see also section 5). The IBCSG Ethics Committee is in charge of judging the ethical implications of any research project involving tissue material. Only upon approval of this ethics committee will a project be pursued. The institutional review board (IRB) and/or ethics committee (EC) responsible for the institution by which the patient was included in the trial will be asked for approval of any new research project with the patient s material. The prior positive decision of the IBCSG Ethics Committee will be distributed to the institutions. The decision of the IRB/EC will also cover patients who have died. Re-consent of the individual patients for a new research project will not be sought, except if declared mandatory by the responsible ethics committee. In case a patient revokes her prior consent for future use of her material, all paraffin embedded material will be sent back to her pathology institute, whereas derived material (RNA, DNA, etc.) will be destroyed. Ongoing research projects including material from such a patient will, however, continue to use the data derived from previous use of her material. In case of incidental findings with immediate clinical relevance for the patient, her treating physician will be informed and will be in charge of contacting the patient based on local regulations. In earlier trials, tissue material was collected without explicit patient consent for future unspecified research. Material from such patients is especially valuable due to the long-term follow-up available for them. Their material will be used in future research after having obtained the approval from the local IRB/EC for each project. 5. Organization and management The IBCSG Executive Committee presides over the IBCSG Tissue Bank. The Director of the Central Pathology Office and the Translational Research Coordinator manage it. The IBCSG Tissue Bank Standard Operating Procedures regulate the work of IBCSG Central Pathology Office personnel. The IBCSG Tissue Bank adequately stores the paraffin-embedded tissue specimens. A quality management system is set up for storage conditions. IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 4/7
5 All aspects of specimen collection, processing and distribution, as well as the details of the patients consent, are stored in the Pathology Material Tracking System (PMTS), an informatics system maintained by the Programming Staff at the Data Management Center. The unique patient/trial identifier is the only key providing the link with the demographic and clinical data of the patient. The institutions that have recruited patients into clinical trials maintain lists of patients and their unique IBCSG patient identifiers. This allows the randomizing institution to identify and contact a patient if necessary. IBCSG Tissue Bank personnel, Data Management Center personnel or Statistical Center personnel cannot identify or contact patients. 6. Technical and operational guidelines All aspects related to the IBCSG Tissue Bank operations are supported by the PMTS, which is linked to other IBCSG informatics systems, ensuring reliable tracking of patient randomization and consent, specimen and data collection, processing, banking and dissemination. The IBCSG Tissue Bank Standard Operating Procedures regulate all these activities. When a patient is randomized, the Central Pathology Office contacts the local pathologist and/or Data Manager and requests the material that is required per protocol for central pathology review and storage at the IBCSG Tissue Bank (Pathology Form, Pathology Reports, paraffin blocks/ representative H&E sections). The samples sent for Central Pathology Review and further research are only marked with the IBCSG randomization number and pathology specimen number, ensuring that the privacy and confidentiality of the patient is protected. The tissue consent level of each patient can be tracked in the PMTS. Blocks /sections are permanently banked in the IBCSG Tissue Bank, unless the submitting pathology institution has asked for some or all the material to be returned for medical or legal reasons or wish of the patient. The paraffin-embedded blocks and glass slides are stored at temperatures below 27ºC / 80 F, in an area with pest and humidity control (1), without any identifiable patient information. 7. Translational Research projects Research projects should be structured according to the checklist of project proposal (Appendix 2) and are submitted to the Translational Research Coordinator. The BPWG is put in charge of assessing the scientific aspects and the priority of each project, which includes assessment of originality, methodology, priority, feasibility. The number of samples needed is determined in collaboration with the Statistical Center. The tissue material is scarce and should be used in the best possible way. Therefore use of each block is carefully IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 5/7
6 assessed with respect to the amount of material to be allocated for a certain project. Once the project description has approval from the BPWG, it is submitted to the Executive Committee for approval, which decides if the project should be submitted to the Scientific Committee and/or the Foundation Council. Every approved project will be submitted to the Ethics committee prior to initiation. For approved projects, the principal investigator of the research facility which will examine the specimens allocated for the project will have to sign an agreement with IBCSG on confidentiality, data and material transfer, and collaboration with the Statistical Center in correlating biomolecular findings with clinical data. Appendix 1: see the document Biological Material Collection PIS-IC.doc Appendix 2: checklist of research proposal submitted to IBCSG applicant(s), institution(s) Title Abstract Starting date, duration Short rationale Short description of planned investigations, timelines Objectives, endpoints Patient selection (which trials, which subgroups of patients) Short descriptions of lab methods and involved labs Material needed o Tissue o Clinical information Use of leftover material after project completion Statistical considerations Ethical considerations Impact on patient Feedback to patient Budget Acceptance of regulations and conditions for applicants Appendix 3: see the document IBCSG Guidelines for Publication and Presentations.doc IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 6/7
7 References: 1.. National Cancer Institute Best Practices for Biospecimen Resources, 2007 National Cancer Institute, United States Department of Health and Human services Best Practices for Repositories,Collection, Storage, Retrieval and Distribution of Biological Materials for Research International Society for Environmental and Biological Repositories (ISBER), USA. Published in CELL PRESERVATION TECHNOLOGY Volume 6, Number 1, 2008, Mary Ann Liebert, Inc., DOI: /cpt Brian R. Leyland-Jones et al. Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials, J Clin Oncol December 1; 26(34): IBCSG Tissue Bank Policy April 2006/ June 2010 v.2 7/7
CTRNet Standard Operating Procedure Haematoxylin & Eosin Staining of Tissue Sections
CTRNet Standard Operating Procedure SOP Number: 08.03.007 Version: e2.0 Supersedes: 8.3.007 e1.0 Category: Material Handling and Documentation Solid Tissue 1.0 PURPOSE Approved By: CTRNet Management Group
I. INTRODUCTION DEFINITIONS AND GENERAL PRINCIPLE
Final: Approved by Partners Professional and Institutional Conduct Committee 8/11/04 Policy on Transfers to Third Parties Of Tissues, Other Specimens, and Data Obtained by Partners-Affiliated Providers
CTRNet Standard Operating Procedure Job Descriptions, Roles and Responsibilities
CTRNet Standard Operating Procedure SOP Number: 01.006 Version: e2.0 Supersedes: 1.1.102 e1.0 Category: Administration 1.0 PURPOSE Approved By: CTRNet Management Group Per: Brent Schacter 01-May-2012 28-May-2012
2016 Call for Projects on ALS Research
2016 Call for Projects on ALS Research 2016 AriSLA Call for Research Projects: PROMOTING RESEARCH EXCELLENCE IN THE FIGHT AGAINST ALS Deadline: at 1.00 pm, March 17 th 2016 1. Aims of the 2016 AriSLA Call
BIOBANK QUALITY. dcarpentieri@phoenixchildrens.com Office: 602-546-1285
BIOBANK QUALITY David F Carpentieri, M.D. Pediatric Pathologist and Biorepository Director, Phoenix Children s Hospital Assistant Professor of Pediatrics and Clinical Pathology, University of Arizona Assistant
INTRODUCTION. Chapter One
Chapter One INTRODUCTION Human tissues have been stored for a long time. Some institutions in the United States have archived specimens of human tissues that are more than 100 years old. Historically,
IRB REVIEW OF USE OF RESEARCH REPOSITORIES
IRB Review of Research Data Repositories at the Portland VA Medical Center IRB REVIEW OF USE OF RESEARCH REPOSITORIES 1. PURPOSE: To set policies and procedures for appropriate establishment, review, approval,
Claim of Exemption Form Page 1 of 6
Claim of Exemption Form Page 1 of 6 Principal Investigator: Phone: Project or Protocol Title: Contact Person: Address: Phone: Fax: E-mail: Copy of Principal Investigator s CV attached SPONSOR / FUNDING
STANDARD OPERATING POLICY AND PROCEDURE
STANDARD OPERATING POLICY AND PROCEDURE SUBJECT: Biospecimen Request and Release Policy Number: 500.0 Policy Date: 1/16/2009 Amendment Date: N/A Revision Date: 5-3-2010 I. INTRODUCTION AND PURPOSE The
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT Regulatory changes will occur for investigators studying human DNA The recent acceleration and widening
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
The Danish Biobank System a unique resource for biomedical research and development
The Danish Biobank System a unique resource for biomedical research and development Professor Stephen Hamilton-Dutoit Chair of Pathology, Aarhus University Denmark Denmark a great little country for biobank
CTRNet Standard Operating Procedure Administration of Standard Operating Procedures
01.005 e2.1 CTRNet Standard Operating Procedure SOP Number: 01.005 Version: e2.1 Supersedes: 01.005 e2.0 Category: Administration Approved By: CTRNet Management Group (CMG) Per: Brent Schacter 01-May-2012
Education and Biobanking as a Career Path
Education and Biobanking as a Career Path Jim Vaught, Ph.D. Editor-in-Chief, Biopreservation and Biobanking Senior Research Fellow, International Prevention Research Institute Traditional biobanking career
A Collaborative Research Partnership Between the Salt River Pima-Maricopa Indian Community and the Translational Genomics Research Institute
A Collaborative Research Partnership Between the Salt River Pima-Maricopa Indian Community and the Translational Genomics Research Institute June 9, 2007 August 16, 2013 1 SRPMIC was committed to finding
Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com
SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,
If you are signing for a minor child, you refers to your child throughout the consent document.
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement
FINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE
Postrefereed, preprint version of the text published at European Journal of Health Law 2013(3)28994. Link to the publisher s website: http://www.brill.com/europeanjournalhealthlaw Sirpa Soini FINLAND ON
The Ethics of Research with Stored Samples and Data
The Ethics of Research with Stored Samples and Data Sara Chandros Hull, Ph.D. Office of the Clinical Director, NHGRI and Department of Bioethics National Institutes of Health Disclaimers/Disclosures No
Taking Part in Research at University Hospitals Birmingham
University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121
RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS
RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS 1. Overview IRB approval and participant informed consent are required to collect biological specimens for research purposes. Similarly, IRB approval
A New Paradigm for Biospecimen Banking in the Personalized Medicine Era
AJCP / Special Article A New Paradigm for Biospecimen Banking in the Personalized Medicine Era Sandra A. McDonald, MD, 1 Mark A. Watson, MD, PhD, 1 Joan Rossi, MA, 2 Colleen M. Becker, RN, MSN, CCRN, 3
PHIA GENERAL INFORMATION
To: From: Researchers Legal Services and Research Services Date: May 21, 2013 Subject: Research and the New Personal Health Information Act On June 1, 2013, the Personal Health Information Act ( PHIA )
CONSENT FORM. Cord Blood Banking for Transplantation
Cord Blood Program Northwest Tissue Center/Puget Sound Blood Center 921 Terry Avenue Seattle, WA 98104 (206) 292-1896 Swedish Medical Center 747 Broadway Seattle, WA 98122 (206) 386-6000 CONSENT FORM Cord
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
2015 AriSLA Ice Bucket Call for Clinical Projects
2015 AriSLA Ice Bucket Call for Clinical Projects Deadline: at 1.00 pm, May 12 th, 2015 1. Background AriSLA, Italian Foundation for research on ALS Amyotrophic Lateral Sclerosis, opens its 2015 Call for
INTERIM SITE MONITORING PROCEDURE
INTERIM SITE MONITORING PROCEDURE 1. PURPOSE The purpose of this SOP is to describe the interim monitoring procedures conducted at Institution, according to GCP and other applicable local regulations.
LSUHSC Biospecimen Core
LSUHSC Biospecimen Core Historical: Traditionally, research involving human blood and tissues in medical institutions involved collaborative efforts among physicians/surgeons and researchers. Often specimens
CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM
APPENDIX A SAMPLE CONSENT FORM CORD BLOOD TRANSPLANTATION (COBLT) STUDY SAMPLE CONSENT FORM FOR THE EXPANDED ACCESS PROTOCOL You (your child) are being asked to take part in a clinical research study.
The Study Site Master File and Essential Documents
The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010
Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE
Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE CRUK Stratified Medicine Initiative Somatic mutation testing for prediction of treatment response in patients with solid tumours:
ETHICS GUIDE FCT INVESTIGATOR PROGRAMME. 25 July 2013
ETHICS GUIDE FCT INVESTIGATOR PROGRAMME 25 July 2013 ETHICAL ISSUES Ethics is central to scientific integrity, honesty and clarity of science. It is considered essential by FCT in the research activities
CONSENT FORM TEMPLATE. Derivation and Distribution of Induced Pluripotent Stem (ips) Cell Lines Created from Donor Specimens
CONSENT FORM TEMPLATE Derivation and Distribution of Induced Pluripotent Stem (ips) Cell Lines Created from Donor Specimens INTRODUCTION We invite you to take part in a research study at [name of research
National Institutes of Health National Cancer Institute Office of Biorepositories and Biospecimen Research
National Institutes of Health National Cancer Institute Office of Biorepositories and Biospecimen Research SUMMARY National Cancer Institute Biospecimen Best Practices Forum The Conference Center at Harvard
Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award
Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award The Cooley s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and
Appendix 1 Waiver of the requirement for informed consent for a clinical trial in a medical emergency Page 1 of 2
Appendix 1 Waiver of the requirement for informed consent for a clinical trial in a medical emergency Page 1 of 2 The Helsinki Committee may approve a clinical trial without the requirement to obtain informed
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not
1.2: DATA SHARING POLICY. PART OF THE OBI GOVERNANCE POLICY Available at: http://www.braininstitute.ca/brain-code-governance. 1.2.
1.2: DATA SHARING POLICY PART OF THE OBI GOVERNANCE POLICY Available at: http://www.braininstitute.ca/brain-code-governance 1.2.1 Introduction Consistent with its international counterparts, OBI recognizes
The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial
The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives
Building the Foundation for Clinical Research Nursing
National Institutes of Health Clinical Center Nursing and Patient Care Services Building the Foundation for Clinical Research Nursing DOMAIN OF PRACTICE FOR THE SPECIALTY OF CLINICAL RESEARCH NURSING 9/4/2009
CIHI Submission: 2011 Prescribed Entity Review
pic pic CIHI Submission: 2011 Prescribed Entity Review October 2011 Who We Are Established in 1994, CIHI is an independent, not-for-profit corporation that provides essential information on Canada s health
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary Introduction Biomedical researchers have long studied human biological materials such as cells collected
Tissue Banking. Advancing Cancer Care
Tissue Banking Advancing Cancer Care Acknowledgments Producer Director Writer Photographer Designer Christina M. Parker, MD Dana-Farber Cancer Institute, Inc. David H. Rose POV-Rose Films Lonnie K. Christiansen
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
TAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
CLINICAL RESEARCH PROTOCOL CHECKLIST
CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND
The Health Information Act. Use and Disclosure of Health Information for Research
The Health Information Act Use and Disclosure of Health Information for Research The Health Information Act (HIA) sets out rules respecting the use and disclosure of health information for research purposes
m 4 Biobank Alliance & m 4 Trial Service Center
m 4 Biobank Alliance & m 4 Trial Service Center Services & Consulting in (non-)clinical development www.m4.de m 4 Biobank Alliance Central Access to High Quality Human Biospecimens for R&D The m 4 Biobank
What Cancer Patients Need To Know
Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking
Site visit inspection report on compliance with HTA minimum standards. MedImmune Ltd. HTA licensing number 12283
Site visit inspection report on compliance with HTA minimum standards MedImmune Ltd HTA licensing number 12283 Licensed under the Human Tissue Act 2004 for the storage of relevant material which has come
MEDICAL MUTUAL Self-Assessment Form
MEDICAL MUTUAL Self-Assessment Form PURPOSE: The purpose of the self-assessment form is to highlight those areas within the non-clinical aspect of office practice including documentation of medical records,
Clinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
Follow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2010 Business process flow diagrams in tissue bank informatics system design, and identification and communication
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
No. 706. Page 1 of 5. Issue Date 4/21/2014
Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page
Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion
Joanna Forbes Senior Clinical Research Nurse Ethical and legal considerations Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion
Cancer Clinical Trials: The Basics
Cancer Clinical Trials: The Basics What Are Cancer Clinical Trials? Research studies involving people Try to answer scientific questions and find better ways to prevent, diagnose, or treat cancer 2 Why
National Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
Guidelines on writing a Research Protocol. Table of Contents. Introduction Page 3
Guidelines on writing a Research Protocol Table of Contents Introduction Page 3 The Structure of a Research Protocol Title of Project Page 4 Investigators and Researchers Main Investigator Co-Investigator/s/Supervisor
CONTROLLED DOCUMENT- DO NOT COPY STANDARD OPERATING PROCEDURE. STH Investigator
Research Department STANDARD OPERATING PROCEDURE STH Investigator Archiving of Essential Documentation Generated During Clinical Research SOP Number A127 Version Number V1.3 Effective Date Author Zoe Whiteley
NSW BRAIN BANKS (NSWBB)
NSW BRAIN BANKS (NSWBB) Incorporating the Sydney Brain Bank and NSW Tissue Resource Centre Guidelines for Researchers Annexure 1 Updated March 2015 Introduction The Sydney Brain Bank (SBB) located at Neuroscience
ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION CALL FOR GRANT APPLICATIONS YEAR 2015
ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION CALL FOR GRANT APPLICATIONS YEAR 2015 December 15 th 2014 The Italian Cystic Fibrosis Research Foundation (FFC) funds a limited number of research projects,
PART I. SECTION 1. The legislature finds that an estimated. 128,000,000 Americans suffer from the crippling economic and
HOUSE OF REPRESENTATIVES TWENTY-FOURTH LEGISLATURE, 2007 STATE OF HAWAII A BILL FOR AN ACT RELATING TO MEDICAL RESEARCH. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: PART I SECTION 1. The legislature
The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy
The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy June 2008 Table of Contents PART V: The Health Insurance Portability and Accountability Act (HIPAA)...
Priority Program Translational Oncology Applicants' Guidelines
Stiftung Deutsche Krebshilfe Dr. h.c. Fritz Pleitgen Präsident Spendenkonto Kreissparkasse Köln IBAN DE65 3705 0299 0000 9191 91 BIC COKSDE33XXX Priority Program Translational Oncology Applicants' Guidelines
The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Sweden
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe Sweden Question 1: What laws or regulations apply to an application for conducting a clinical trial in Sweden?
Implementing Honest Broker System(s) in Academic Medical Centers: The Pittsburgh Experience
Implementing Honest Broker System(s) in Academic Medical Centers: The Pittsburgh Experience Christopher Ryan, Ph.D., CIP IRB Director Professor of Psychiatry University of Pittsburgh ryancm@upmc.edu The
Ethical, Legal and Societal consideration in the design of Canadian Longitudinal Study on Aging (CLSA) Parminder Raina, Susan Kirkland and Christina
Ethical, Legal and Societal consideration in the design of Canadian Longitudinal Study on Aging (CLSA) Parminder Raina, Susan Kirkland and Christina Wolfson McMaster University BCNAR Vancouver February
EDCTP-TDR Clinical Research and Development Fellowship Training Plan
EDCTP-TDR Clinical Research and Development Fellowship Training Plan 1 Administrative information Grant reference number Name of Fellow Home organisation, country Supervisor at home organisation Name Job
Competency Portfolio for the Diploma in Cytopathology
Competency Portfolio for the Diploma in Cytopathology Guide for Working Group/AFC-Diploma Committee, Educators, and Candidates 2013 EDITIAL REVISION 2015 VERSION 1.2 This portfolio applies to those who
Guidelines for applicants
ERACoSysMed 1st Joint Transnational Call for Proposals for European Research Projects to demonstrate the feasibility and benefits of systems medicine Guidelines for applicants Submission deadline for pre-proposals:
PROPOSAL ACRONYM - ETN / EID / EJD (delete as appropriate and include as header on each page) START PAGE MARIE SKŁODOWSKA-CURIE ACTIONS
START PAGE MARIE SKŁODOWSKA-CURIE ACTIONS Innovative Training Networks (ITN) Call: H2020-MSCA-ITN-2015 PART B PROPOSAL ACRONYM This proposal is to be evaluated as: [ETN] [EID] [EJD] [delete as appropriate]
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
Principal Investigator and Sub Investigator Responsibilities
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
Credentialing Procedure for UVM Personnel Carrying Out Clinical Research At The University of Vermont Medical Center
Credentialing Procedure for UVM Personnel Carrying Out Clinical Research At The University of Vermont Medical Center Clinicians and support personnel carrying out diagnosis, prognosis or treatment of patients
Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical
Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical Research Finance The University of Texas MD Anderson Cancer
QS01-H. Internal Audits
QS01-H Internal Audits Version: F01 Valid from: Replaces version: -- of: -- Author: Edith Belz Date Author signature Review: FG-QM Date FG-QS Approval: Board KKS Network Date Board spokesperson Target
Supporting Cancer Clinical Trials in Australia Principles Document
Supporting Cancer Clinical Trials in Australia Principles Document Introduction Cancer Australia is an Australian Government agency established to help reduce the impact of cancer in the community. It
2015 FCT INVESTIGATOR GRANTS GUIDE ON ETHICAL ISSUES
2015 FCT INVESTIGATOR GRANTS GUIDE ON ETHICAL ISSUES GUIDE ON ETHICAL ISSUES Ethics is central to scientific integrity, honesty and clarity of science. It is considered essential by the FCT in the research
Health Information Technology/Informatics (Policy Number)
The American Society For Clinical Pathology Policy Statement Health Information Technology/Informatics (Policy Number) Policy Statement: ASCP supports the implementation of standardized health information
CALL FOR PARTNERSHIP MULTIPLI PROGRAM
CALL FOR PARTNERSHIP MULTIPLI PROGRAM I. Introduction The MULTIPLI program, coordinated by Inserm (the French National Institute of Health and Medical Research) and the Cancer Institute of the French National
Quality Biobanking Operations and Practices connecting the biobank with downstream applications increasing the value of your biobank
National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Quality Biobanking Operations and Practices connecting the biobank with downstream applications increasing
JDRF Scientific Guidelines for applicants Version/Date 002/Aug 2015 Version history 001/Jul 2011
JDRF Scientific Guidelines for applicants Version/Date 002/Aug 2015 Version history 001/Jul 2011 Contents Introduction... 2 JDRF clinical terms of award... 3 Nonexempt human subject s research... 3 Full
BioGrid s use of Business Analytics for Collaborative Medical Research. Maureen Turner, CEO, BioGrid Australia
BioGrid s use of Business Analytics for Collaborative Medical Research Maureen Turner, CEO, BioGrid Australia Overview Data sharing considerations BioGrid a collaborative model Data ethics, privacy, security
Awards and Grants Policies Updated January 2016
Awards and Grants Policies Updated January 2016 Failure to comply with Foundation award policies will hinder an awardee s eligibility to receive additional Foundation funding. Failure to comply by Foundation
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood
Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood Supreme Council of Health Department of Research Guidance Regarding Research Involving Human Embryonic
Patient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
Orientation Manual for Clinical Research Coordinators
Orientation Manual for Clinical Research Coordinators Maine Medical Center Research Institute Page 1 of 19 Version 1 (2009) MAINE MEDICAL CENTER RESEARCH INSTITUTE Statement of Mission, Vision, Goals and
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Alberta Electronic Health Record Regulation Section 5 Framework September 2011 Version 1.1
Alberta Electronic Health Record Regulation Section 5 Framework September 2011 Version 1.1 Acknowledgements The College of Physicians & Surgeons of Alberta thanks the following stakeholders for their valuable
Study Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
Comprehensive Sample Management Solutions
Comprehensive Sample Management Solutions Discover the Hidden Value in Your Sample Assets solutions consulting sample storage sample bioprocessing onsite/offsite operations management logistics/relocation
Yale University Open Data Access (YODA) Project Procedures to Guide External Investigator Access to Clinical Trial Data Last Updated August 2015
OVERVIEW Yale University Open Data Access (YODA) Project These procedures support the YODA Project Data Release Policy and more fully describe the process by which clinical trial data held by a third party,
Taking Part in Cancer Treatment Research Studies
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health This booklet is for people with cancer, their family,
IT-Support Requirement Catalog for Biobank Management
IT-Support Requirement Catalog for Biobank Management A) Module Organization and Operation of a Biobank 12 requirement categories were defined and detailed requirements were described to support the role
Integrating a Research Management System & EMR: Motivations and Benefits Host
Integrating a Research Management System & EMR: Motivations and Benefits Host Lisa Haddican, Content Marketing Specialist Specialized Solutions by Forte Developed with the expertise of 20,000 trials Clinical
How Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
Template for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous